Literature DB >> 31838282

Bioanalytical method development and validation of corynantheidine, a kratom alkaloid, using UPLC-MS/MS, and its application to preclinical pharmacokinetic studies.

Tamara I King1, Abhisheak Sharma2, Shyam H Kamble2, Francisco León3, Erin C Berthold1, Raluca Popa1, Orélia Cerlati4, Boone M Prentice4, Lance R McMahon5, Christopher R McCurdy6, Bonnie A Avery2.   

Abstract

Corynantheidine, a minor alkaloid found in Mitragyna speciosa (Korth.) Havil, has been shown to bind to opioid receptors and act as a functional opioid antagonist, but its unique contribution to the overall properties of kratom remains relatively unexplored. The first validated bioanalytical method for the quantification of corynantheidine in rat plasma is described. The method was linear in the dynamic range from 1-500 ng/mL, requires a small plasma sample volume (25 μL), and a simple protein precipitation method for extraction of the analyte. The separation was achieved with Waters BEH C18 2.1 × 50 mm column and the 3-minute gradient of 10 mM ammonium acetate buffer (pH = 3.5) and acetonitrile as mobile phase. The method was validated in terms of accuracy, precision, selectivity, sensitivity, recovery, stability, and dilution integrity. It was applied to the analysis of the male Sprague Dawley rat plasma samples obtained during pharmacokinetic studies of corynantheidine administered both intravenously (I.V.) and orally (P.O.) (2.5 mg/kg and 20 mg/kg, respectively). The non-compartmental analysis performed in Certara Phoenix® yielded the following parameters: clearance 884.1 ± 32.3 mL/h, apparent volume of distribution 8.0 ± 1.2 L, exposure up to the last measured time point 640.3 ± 24.0 h*ng/mL, and a mean residence time of 3.0 ± 0.2 h with I.V. dose. The maximum observed concentration after a P.O. dose of 213.4 ± 40.4 ng/mL was detected at 4.1 ± 1.3 h with a mean residence time of 8.8 ± 1.8 h. Absolute oral bioavailability was 49.9 ± 16.4 %. Corynantheidine demonstrated adequate oral bioavailability, prolonged absorption and exposure, and an extensive extravascular distribution. In addition, imaging mass spectrometry analysis of the brain tissue was performed to evaluate the distribution of the compound in the brain. Corynantheidine was detected in the corpus callosum and some regions of the hippocampus.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Alkaloid; Corynantheidine; Kratom; Mitragyna speciosa; Pharmacokinetics; UPLC-MS/MS

Mesh:

Substances:

Year:  2019        PMID: 31838282      PMCID: PMC7350276          DOI: 10.1016/j.jpba.2019.113019

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  27 in total

1.  The metabolism of corynantheidine and 9-methoxycorynantheidine-type alkaloids by liver microsomes.

Authors:  A H Beckett; D M Morton
Journal:  Biochem Pharmacol       Date:  1967-08       Impact factor: 5.858

2.  Substance P receptor in the rat indusium griseum during postnatal development.

Authors:  Paolo Barbaresi
Journal:  Neurosci Res       Date:  2017-08-23       Impact factor: 3.304

3.  Update on the Pharmacology and Legal Status of Kratom.

Authors:  Walter C Prozialeck
Journal:  J Am Osteopath Assoc       Date:  2016-12-01

4.  Cellular localization of adrenergic receptors in rat and human brain.

Authors:  R Cash; R Raisman; L Lanfumey; A Ploska; Y Agid
Journal:  Brain Res       Date:  1986-04-02       Impact factor: 3.252

Review 5.  Physiological parameters in laboratory animals and humans.

Authors:  B Davies; T Morris
Journal:  Pharm Res       Date:  1993-07       Impact factor: 4.200

6.  Simultaneous quantification of ten key Kratom alkaloids in Mitragyna speciosa leaf extracts and commercial products by ultra-performance liquid chromatography-tandem mass spectrometry.

Authors:  Abhisheak Sharma; Shyam H Kamble; Francisco León; Nelson J-Y Chear; Tamara I King; Erin C Berthold; Surash Ramanathan; Christopher R McCurdy; Bonnie A Avery
Journal:  Drug Test Anal       Date:  2019-05-15       Impact factor: 3.345

7.  Studies on the synthesis and opioid agonistic activities of mitragynine-related indole alkaloids: discovery of opioid agonists structurally different from other opioid ligands.

Authors:  Hiromitsu Takayama; Hayato Ishikawa; Mika Kurihara; Mariko Kitajima; Norio Aimi; Dhavadee Ponglux; Fumi Koyama; Kenjiro Matsumoto; Tomoyuki Moriyama; Leonard T Yamamoto; Kazuo Watanabe; Toshihiko Murayama; Syunji Horie
Journal:  J Med Chem       Date:  2002-04-25       Impact factor: 7.446

8.  Autoradiographic distribution of mu and delta opiate receptors in rat brain using highly selective ligands.

Authors:  R Quirion; J M Zajac; J L Morgat; B P Roques
Journal:  Life Sci       Date:  1983       Impact factor: 5.037

9.  Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids.

Authors:  Samuel Obeng; Shyam H Kamble; Morgan E Reeves; Luis F Restrepo; Avi Patel; Mira Behnke; Nelson J-Y Chear; Surash Ramanathan; Abhisheak Sharma; Francisco León; Takato Hiranita; Bonnie A Avery; Lance R McMahon; Christopher R McCurdy
Journal:  J Med Chem       Date:  2019-12-27       Impact factor: 7.446

10.  Substance P NK1 receptor in the rat corpus callosum during postnatal development.

Authors:  Paolo Barbaresi; Emanuela Mensà; Guendalina Bastioli; Salvatore Amoroso
Journal:  Brain Behav       Date:  2017-05-02       Impact factor: 2.708

View more
  5 in total

1.  Pharmacokinetics of Eleven Kratom Alkaloids Following an Oral Dose of Either Traditional or Commercial Kratom Products in Rats.

Authors:  Shyam H Kamble; Erin C Berthold; Tamara I King; Siva Rama Raju Kanumuri; Raluca Popa; Julius R Herting; Francisco León; Abhisheak Sharma; Lance R McMahon; Bonnie A Avery; Christopher R McCurdy
Journal:  J Nat Prod       Date:  2021-02-23       Impact factor: 4.050

2.  Searching for a Signal: Self-Reported Kratom Dose-Effect Relationships Among a Sample of US Adults With Regular Kratom Use Histories.

Authors:  Kirsten E Smith; Jeffrey M Rogers; Kelly E Dunn; Oliver Grundmann; Christopher R McCurdy; Destiny Schriefer; David H Epstein
Journal:  Front Pharmacol       Date:  2022-03-01       Impact factor: 5.810

Review 3.  Kratom Abuse Potential 2021: An Updated Eight Factor Analysis.

Authors:  Jack E Henningfield; Daniel W Wang; Marilyn A Huestis
Journal:  Front Pharmacol       Date:  2022-01-28       Impact factor: 5.810

4.  Pharmacokinetic Analysis of Diosgenin in Rat Plasma by a UPLC-MS/MS Approach.

Authors:  Pei Liu; Lin Xu; Jing-Han Guo; Jin-Hua Chang; Xi-Gang Liu; He-Fei Xue; Ru-Xing Wang; Zhong-Si Li; Guang-Xin Miao; Cui-Zhe Liu; Jian-Yu Zhou
Journal:  J Anal Methods Chem       Date:  2022-09-30       Impact factor: 2.594

5.  Kratom Alkaloids as Probes for Opioid Receptor Function: Pharmacological Characterization of Minor Indole and Oxindole Alkaloids from Kratom.

Authors:  Soumen Chakraborty; Rajendra Uprety; Amal E Daibani; Valerie L Rouzic; Amanda Hunkele; Kevin Appourchaux; Shainnel O Eans; Nitin Nuthikattu; Rahul Jilakara; Lisa Thammavong; Gavril W Pasternak; Ying-Xian Pan; Jay P McLaughlin; Tao Che; Susruta Majumdar
Journal:  ACS Chem Neurosci       Date:  2021-07-02       Impact factor: 5.780

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.